Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $16.07 USD
Change Today +0.21 / 1.32%
Volume 283.2K
SGNT On Other Exchanges
As of 8:10 PM 10/5/15 All times are local (Market data is delayed by at least 15 minutes).

sagent pharmaceuticals inc (SGNT) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/14/14 - $33.60
52 Week Low
10/2/15 - $14.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

sagent pharmaceuticals inc (SGNT) Related Businessweek News

No Related Businessweek News Found

sagent pharmaceuticals inc (SGNT) Details

Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, sources, manufactures, and markets pharmaceutical products, principally injectable-based generic equivalents to branded products in North America. The company offers anti-infective products, such as Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structures, as well as moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients; and Levofloxacin, a fluoroquinolone antibacterial for the treatment of infections caused by susceptible bacteria, including nosocomial and community acquired pneumonia, sinusitis, chronic bronchitis, skin and skin structure infections, prostatitis, urinary tract infection, and pyelonephritis in adults of age 18 years or older. It also provides oncology products consisting of Leucovorin Calcium, a folic acid derivative used to prevent harmful effects of methotrexate when methotrexate is used to treat certain types of cancer; and Zoledronic Acid, a bisphosphonate given intravenously to prevent skeletal fractures in patients with cancers, such as multiple myeloma and prostate cancer, as well as for treating osteoporosis. In addition, the company offers critical care products comprising Heparin, an anticoagulant used to prevent and treat blood clotting during and after surgery and dialysis; and Propofol, a sedative used to induce and maintain general anesthesia during surgical procedures. As of December 31, 2014, its product portfolio included 54 marketed products. Sagent Pharmaceuticals, Inc. sells its products to hospitals, integrated delivery networks, and alternative site facilities through pharmaceutical wholesalers and specialty distributors. The company was formerly known as Sagent Holding Co. and changed its name to Sagent Pharmaceuticals, Inc. in April 2011. Sagent Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Schaumburg, Illinois.

466 Employees
Last Reported Date: 03/16/15
Founded in 2006

sagent pharmaceuticals inc (SGNT) Top Compensated Officers

President, Chief Legal Officer and Corporate ...
Total Annual Compensation: $328.9K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $344.8K
Executive Vice President of National Accounts...
Total Annual Compensation: $297.1K
Compensation as of Fiscal Year 2014.

sagent pharmaceuticals inc (SGNT) Key Developments

Sagent Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Month Ended June 30, 2015; Revises Earnings Guidance for the Year 2015

Sagent Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six month ended June 30, 2015. For the quarter, the company reported net revenue of $77,345,000 against $69,194,000 a year ago. The increase was driven primarily by the $8.1 million from the addition of Omega on October 1, 2014. Income from operations was $1,191,000 against $3,318,000 a year ago. Income before income taxes was $1,575,000 against $3,242,000 a year ago. Net loss was $256,000 or $0.01 per basic and diluted share against net income of $3,069,000 or $0.09 per diluted share a year ago. Adjusted EBITDA was $6,222,000 against $7,354,000 a year ago. EBITDA was $4,700,000 against $6,096,000 a year ago. The decline in adjusted EBITDA is primarily driven by a $5.3 million decline in adjusted margin, primarily as a result of the loss of the Actavis products effective January 1 of 2015. This was offset by $4.2 million of reduced product development spending, primarily related to the timing of milestone payments. For the six months, the company reported net revenue of $159,990,000 against $140,063,000 a year ago. Income from operations was $1,002,000 against $9,950,000 a year ago. Net loss was $2,150,000 or $0.07 per basic and diluted share against net income of $8,188,000 or $0.25 per diluted share a year ago. Adjusted EBITDA was $15,229,000 against $16,708,000 a year ago. EBITDA was $6,503,000 against $14,254,000 a year ago. The increase in revenue was driven by base business performance and a $15.5 million contribution from Omega. The company reported net loss due to impact of interest, other non operating expenses. With a lower than anticipated impact from new business development activities and GPO contract renewals, the company has revised the earnings outlook for 2015. For the fiscal year ended December 31, 2015, the company expects net loss to be in the range of $3 million to $7 million. EBITDA is expected to be in the range of $10 million to $18 million. Adjusted EBITDA is expected to be in the range of $20 million to $30 million. Net revenue for the year is expected to be in the range of $305 million to $330 million, a reduction from the previous guidance of $325 million to $375 million. Adjusted gross profit as a percentage of net revenue in the range of 25% to 28%, a decline from initial estimates of 27% to 31%. Depreciation and amortization expense is to be in the range between from $12 million to $16 million and net interest expense is to be $1 million.

Sagent Pharmaceuticals Seeks Acquisitions

Sagent Pharmaceuticals, Inc. (NasdaqGS:SGNT) said, "As such, we continue to invest in our pipeline and to pursue acquisition opportunities of both products and businesses to enhance our commercial portfolio, our pipeline, and our profitability. We are also engaged with our partners to continue to exploit their development and manufacturing capabilities and capacities through our unique commercial infrastructure."

Sagent Pharmaceuticals Appoints Allan Oberman as Chief Executive Officer and a Member of the Board of Directors

Sagent Pharmaceuticals, Inc. announced that its Board of Directors has named Allan Oberman as Chief Executive Officer and a member of the Board of Directors, effective immediately upon receipt of a US work visa. Mr. Oberman most recently served as President and Chief Executive Officer of Teva Americas Generics from November 2012 until December 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGNT:US $16.07 USD +0.21

SGNT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $11.59 USD -0.10
OraSure Technologies Inc $4.71 USD 0.00
Pernix Therapeutics Holdings Inc $3.28 USD +0.04
SciClone Pharmaceuticals Inc $7.05 USD +0.14
Sucampo Pharmaceuticals Inc $21.30 USD -0.18
View Industry Companies

Industry Analysis


Industry Average

Valuation SGNT Industry Range
Price/Earnings 17.4x
Price/Sales 1.7x
Price/Book 1.9x
Price/Cash Flow 17.5x
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAGENT PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at